Edition:
United States

Amgen Inc (AMGN.OQ)

AMGN.OQ on NASDAQ Stock Exchange Global Select Market

169.96USD
22 Nov 2017
Change (% chg)

$0.12 (+0.07%)
Prev Close
$169.84
Open
$169.86
Day's High
$170.58
Day's Low
$169.37
Volume
461,489
Avg. Vol
993,564
52-wk High
$191.08
52-wk Low
$138.83

Chart for

About

Amgen Inc. is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. It operates in human therapeutics segment. Its marketed products portfolio includes Neulasta (pegfilgrastim); erythropoiesis-stimulating agents (ESAs), such as Aranesp (darbepoetin alfa) and EPOGEN... (more)

Overall

Beta: 1.38
Market Cap(Mil.): $123,375.80
Shares Outstanding(Mil.): 725.91
Dividend: 1.15
Yield (%): 2.71

Financials

  Industry Sector
P/E (TTM): -- 31.56 15.47
EPS (TTM): -- -- --
ROI: -- 15.17 11.81
ROE: -- 16.58 15.76

BRIEF-Amgen launches Enbrel Mini with Autotouch in U.S.

* Amgen launches the Enbrel Mini single-dose prefilled cartridge with autotouch reusable autoinjector that is ergonomically designed for patients

Nov 17 2017

BRIEF-Temasek Holdings takes share stake in Vantiv Inc, raises share stake in Amgen

* Temasek Holdings (Private) Ltd takes share stake of 982,057 Class A shares in Vantiv Inc - SEC filing

Nov 14 2017

BRIEF-Amgen receives positive CHMP opinion to expand use of Nplate in pediatric patients with chronic immune thrombocytopenic purpura

* Amgen receives positive CHMP opinion to expand use of Nplate® (romiplostim) in pediatric patients with chronic immune thrombocytopenic purpura

Nov 10 2017

BRIEF-Amgen and Allergan receive positive chmp opinion for ABP 215

* Amgen and Allergan receive positive CHMP opinion for ABP 215 (biosimilar bevacizumab) for the treatment of certain types of cancer

Nov 10 2017

BRIEF-Amgen announces new analyses of high-risk patient subgroups

* Announces new analyses of high-risk patient subgroups from Repatha (evolocumab) cardiovascular outcomes study at AHA Scientific Sessions 2017 Source text for Eikon: Further company coverage:

Nov 06 2017

BRIEF-Amgen, Novartis announce expanded collaboration with Banner Alzheimer's Institute

* Amgen and Novartis announce expanded collaboration with Banner Alzheimer's Institute in pioneering prevention program

Nov 02 2017

Japan's Kirin cashes out of Amgen drug joint venture

TOKYO Japan's Kirin Holdings Co Ltd said on Tuesday it would sell its share in a pharmaceutical research joint venture with California-based drugmaker Amgen Inc for $780 million.

Oct 31 2017

Japan's Kirin cashes out of Amgen drug joint venture

TOKYO, Oct 31 Japan's Kirin Holdings Co Ltd said on Tuesday it would sell its share in a pharmaceutical research joint venture with California-based drugmaker Amgen Inc for $780 million.

Oct 31 2017

BRIEF-‍Kirin-Amgen joint venture to become wholly-owned subsidiary of Amgen​

* ‍Kirin-Amgen joint venture to become wholly-owned subsidiary of Amgen​

Oct 31 2017

BRIEF-Kirin says terminating shareholders' agreement of JV with Amgen

* Says terminating shareholders' agreement of joint venture with Amgen

Oct 31 2017

Earnings vs. Estimates